title: Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?
abstract: A small proportion of patients with advanced hepatocellular carcinoma harbor FGF3/4 gene amplifications in an 11q13 amplicon. A recent report suggests that the presence of this alteration might enrich for sensitivity to sorafenib. Further, there is growing evidence that interference with the FGF/FGFR axis has therapeutic potential in patients with advanced hepatocellular carcinoma.
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
authors.forename: James J
authors.initials: JJ
authors.lastname: Harding
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
authors.forename: Ghassan K
authors.initials: GK
authors.lastname: Abou-Alfa
keywords: Hepatocellular carcinoma (HCC); brivanib; fibroblast growth factor (FGF); sorafenib; targeted therapy